Microsaic Systems plc (AIM: MSYS), the developer of chip – based scientific instruments, is pleased to announce the appointment of Mr Christopher Buckley to its Board of Directors.
Mr Buckley has more than 30 years of international marketing and general management experience in the global Pharmaceutical industry with a proven track record of translating scientific innovations into competitive customer-focused benefits. Most recently, he was a Global Brand Director at Novartis, at which he spent the majority of his career progressing through a variety of local, regional and global roles. He brings Microsaic a wealth of strategic management experience, coupled with the pragmatic and commercial expertise to effectively grow global brands. Mr Buckley holds a B.Sc. Hons in Pharmacology and Physiology from the University of Aston, UK.
Colin Nicholl, Microsaic Chairman, said: “ Microsaic has made an encouraging start to 2016 executing its new strategy and building on progress in the second half of last year. We are therefore delighted to welcome Chris Buckley to the Board We look forward to his contribution to the delivery of important commercial milestones that aim to capture further value from the Company’s suite of miniaturised analytical instruments and innovative technologies.”
No further information is required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules for Companies in respect of the appointment of Christopher Buckley (aged 54 ) to the board.